Представленная информация о лекарственных средствах предназначена исключительно для ознакомления и не является офертой, рекламой или инструкцией по применению. Продажа, доставка и назначение препаратов через сайт не осуществляются. По вопросам применения препарата вы можете записаться на очный прием или онлайн-консультацию у профильного специалиста нашей клиники.
INCRESYNC (ITALY)
Active ingredient: Alogliptin / Pioglitazone
106у.е.
Incresync 25/30 mg is a medication that combines two active ingredients for the treatment of certain conditions. It is intended for patients who require effective therapy. It is important to consult a doctor to ensure that this medication is suitable for you.
Pharmacological group: Antidiabetic agent
Trade name: Incresync
Manufacturer: Hikma
Dosage form: Film-coated tablets
Standard dosages: 25 mg / 30 mg
Indications for use
Main indication: Treatment of type 2 diabetes mellitus
Additional (off-label): May be used in combination with other antidiabetic agents
Target group: Adult patients
Mechanism of action
Incresync combines two different mechanisms to control blood sugar levels in patients with type 2 diabetes.
• Alogliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that increases incretin levels, promoting insulin secretion and reducing glucagon levels.
• Pioglitazone is a thiazolidinedione derivative that enhances tissue (muscle, fat, and liver) sensitivity to insulin.
Together, these components provide a comprehensive approach to glycemic control.
Important safety information
Common side effects:
• Headache
• Nausea
• Weight gain
• Edema
Main warnings and precautions:
• Risk of hypoglycemia when used with insulin or sulfonylureas
• Risk of heart failure
• Possible risk of bladder cancer
• Fluid retention
Contraindications:
• Hypersensitivity to the components of the medication
• History of severe heart failure
Drug interactions:
• Insulin and sulfonylureas (increased risk of hypoglycemia)
• Warfarin (possible alteration of its effect)
Special instructions:
Be sure to inform your doctor about all medications you are taking to avoid unwanted interactions. Regular monitoring of blood sugar levels and liver function is necessary during therapy.
The package contains 28 tablets.
Pharmacological group: Antidiabetic agent
Trade name: Incresync
Manufacturer: Hikma
Dosage form: Film-coated tablets
Standard dosages: 25 mg / 30 mg
Indications for use
Main indication: Treatment of type 2 diabetes mellitus
Additional (off-label): May be used in combination with other antidiabetic agents
Target group: Adult patients
Mechanism of action
Incresync combines two different mechanisms to control blood sugar levels in patients with type 2 diabetes.
• Alogliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that increases incretin levels, promoting insulin secretion and reducing glucagon levels.
• Pioglitazone is a thiazolidinedione derivative that enhances tissue (muscle, fat, and liver) sensitivity to insulin.
Together, these components provide a comprehensive approach to glycemic control.
Important safety information
Common side effects:
• Headache
• Nausea
• Weight gain
• Edema
Main warnings and precautions:
• Risk of hypoglycemia when used with insulin or sulfonylureas
• Risk of heart failure
• Possible risk of bladder cancer
• Fluid retention
Contraindications:
• Hypersensitivity to the components of the medication
• History of severe heart failure
Drug interactions:
• Insulin and sulfonylureas (increased risk of hypoglycemia)
• Warfarin (possible alteration of its effect)
Special instructions:
Be sure to inform your doctor about all medications you are taking to avoid unwanted interactions. Regular monitoring of blood sugar levels and liver function is necessary during therapy.
The package contains 28 tablets.
